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Management of focal segmental glomerulosclerosis: Evidence- to 12% for those with proteinuria [4, 5]. The etiology is
based recommendations. Focal segmental glomerulosclerosis unknown, and for reasons that are unclear, the preva-
(FSGS) is a diagnosis based on the presence of glomeruli with
lence of primary FSGS appears to be increasing [2].segmental scarring in association with intracapillary foam cells
and adhesions. To develop evidence-based treatment guide-
lines, a MEDLINE search was conducted, and articles were
reviewed using levels of evidence. Graded recommendations NATURAL HISTORY
were developed according to the level of evidence. There was
In adults, FSGS presents with asymptomatic protein-limited evidence found on which to develop recommendations.
Treatment with prednisone of 0.5 to 2 mg/kg/day should be uria in approximately half of the cases and with features
considered in all patients and continued for six months before of the nephrotic syndrome in half. Hypertension and adeclaring the patient resistant to therapy. Remission is associ-
reduction in renal function are also commonly seen. Inated with the use of high doses (more than 60 mg/day) for
three months; therefore, if there is a concern about prolonged approximately one third of the cases, microscopic hema-
use, a reduction in dose to 0.5 mg/kg/day should be made only turia is present, even in the absence of urinary or respira-
after three months (grade D).
tory tract infection [3, 4]. The clinical course of thisThe use of cyclosporine A (CsA) at doses to maintain serum
condition varies. In patients who have had a treatment-levels at 150 to 300 mg/ml may be effective in reducing urinary
protein excretion. Relapse after reducing or stopping CsA is induced complete remission, the course of disease ap-
very common. Long-term use may be required to maintain pears to be stable. In patients who have been treated
remission (grade D).
but have not had a remission, there is deterioration ofThe use of cytotoxic therapy (cyclophosphamide, azathio-
prine, and chlorambucil) for adults is second-line therapy renal function, with a large portion of patients (30 to
(grade D). 63%) developing renal failure [6–11]. Untreated ne-
Plasmapheresis or protein adsorption may be recommended phrotic patients have been described as having an out-for renal transplant patients with recurrent FSGS (grade D).
come similar to those who failed a trial of therapy. Un-
treated non-nephrotic patients may have a better
outcome than the untreated nephrotic patients, but re-In 1957, Rich originally reported focal segmental glo-
ports are mixed in this patient population. However,merulosclerosis (FSGS) from a postmortem study of 20
follow-up in retrospective studies usually extends to onlychildren with nephrotic syndrome [1]. He described glo-
two to five years, and this may not be adequate in suchmerulosclerosis, focal and segmental in location, devel-
a heterogenous condition.oping initially in juxtamedullary glomeruli and prog-
ressing to involve all glomeruli. Subsequently, there have Negative prognostic indicators are similar to those in
been detailed descriptions of what may be variants of other glomerular diseases: an increased serum creatinine
FSGS or different stages in the evolution of the glomeru- level at diagnosis and interstitial scarring on renal biopsy
lopathy. The prevalence of FSGS among patients with [11]. Two other indicators—nephrotic range proteinuria
glomerulonephritis varies with the indications for renal and hypertension—are not cited consistently [7–9, 11, 12].
biopsy at different institutions from 2.5 to 18.7% of pa- These indicators do not forecast which patients will re-
tients undergoing renal biopsy for all causes [2, 3] or 7 spond to therapy but do predict long-term outcome [11].
Some patients have a malignant clinical course with
rapid deterioration in renal function and are unrespon-Key words: sclerosis, segmental scarring, prednisone, cyclosporine A,
recurrent FSGS. sive to therapy [12]. Recurrence in renal allografts in
this population is common (15 to 55%) [12–14]. 1999 by the International Society of Nephrology
S-26
Burgess: Focal segmental glomerulosclerosis S-27
Table 1. Levels of evidenceDEFINITIONS
Level 1: RCT with hard end-pointRenal biopsy findings
Level 2: RCT with surrogate end-point
Terms used in renal pathology must be clear to ensure Level 3: Non-R trial with a control group, or subgroup
analysis of an RCTappropriate referencing. The term focal means that only
Level 4: Before and after studysome glomeruli in the biopsy are involved, whereas seg- Level 5: Case series .10 patients
mental refers to involvement of only some lobules of Level 6: Case series ,10 patients
any given glomerulus. Global sclerosis refers to the total Recommendations
involvement of one entire glomerulus. Variants of the Grade A: Based upon Level 1 evidence
Grade B: Based upon Level 2 evidencedisease exist: diffuse mesangial hypercellularity, tip le-
Grade C: Based upon Level 3 evidencesion (the segmental lesion is adjacent to the epithelial Grade D: Based upon Level 4 or lower evidence or expert
cells of the early proximal tubule and to the tubular opinion
pole of Bowman’s capsule), capillary collapse, and focal Abbreviations are: RCT, randomized clinical trial; R, randomized.
glomerular obsolescence. Biopsy findings similar to idio-
pathic FSGS are found secondary to known etiologic
agents such as human immunodeficiency virus (HIV) or
proven diagnosis. Because many reports include otherheroin. These and other forms of secondary FSGS must
patients (children or patients treated without renalbe ruled out when patients are to be included in studies
biopsy), the sample size noted in the tables may beor clinically treated [2].
smaller than the total reported in the articles. Limiting
Clinical status the review to adult FSGS patients often leaves an inade-
quate sample size for definitive evidence and lowers theThe definitions for complete and partial remission of-
level of evidence [15].ten differ between authors. A complete remission may
mean reduction of urinary protein excretion to zero, less
than 250 mg, or less than 300 mg/day, whereas partial
RECOMMENDATIONSremission may refer to a reduction of daily proteinuria
Recommendation 1to 0.3 to 2.0 g/day, or a reduction to below nephrotic-
range proteinuria. Similarly, definitions of renal insuffi- Treatment with prednisone of 0.5 to 2.0 mg/kg/day
ciency differ, for example, a serum creatinine of more should be considered for patients with FSGS. Treatment
than 1.5 mg/dl, a creatinine clearance of less than 0.8 ml/ should continue for a total duration of six months before
seconds, or a doubling of serum creatinine. Regardless declaring the patient steroid resistant. Remission is asso-
of the variance of these definitions for these terms across ciated with a dose of at least 60 mg/day. If necessary,
articles, the outcomes appear to be consistent. the dose may be reduced to 0.5 mg/kg/day, but only after
three months (grade D).
METHODS Evidence
Evidence was initially compiled with a MEDLINE An overview of the evidence reveals several key find-
literature search using a primary search technique for ings about prednisone therapy. The dose of prednisone
review and clinical research articles. Secondary searches needs to be approximately 60 mg/day initially. The dura-
were done using the reference lists of review articles
tion of therapy needs to be approximately six months
retrieved initially, and searches of personal files were
before concluding that the patient is resistant to predni-also done. Published articles were categorized according
sone therapy; no clinical or biopsy finding predicts theto design methodology and were reviewed and graded
response to therapy. Adults respond as well as childrenfor level of evidence using guidelines published pre-
to therapy. Complete remission predicts a good long-viously by the Canadian Hypertension Society [15];
term outcome, and nontreatment or lack of response tograded recommendations were developed based on the
treatment predicts poor outcome with the developmentevidence (Table 1).
of chronic renal failure (CRF).
A summary of the relevant studies is presented in
MANAGEMENT Table 2 [6–9, 11, 12, 16–18]. There have been no random-
ized clinical trials of steroid therapy; most reports areArticles describing the clinical course or reporting clin-
case series, with or without controls, and are thus catego-ical trials of patients with FSGS often included patients
rized as level 4 or 5 evidence. Most early reports providedwith steroid-resistant, steroid-dependent, or frequently
few details, if any, on the dose or duration of therapy.relapsing nephrotic syndrome, without a definitive renal
Response rates varied tremendously. Lim, Sibley andbiopsy diagnosis. The studies reviewed in this article
are predominantly those including adults with a biopsy- Spargo reported no responders from 10 FSGS patients
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Table 2. Corticosteroid therapy reports
# Responders/
Level of # treated
evidence Author [Ref] # Adults Treatment remission rate % Rate of CRF
Level 4
St Hillier [16] Total 85, NS 30 17/30 NS treated 16/17 (94%)
Non-NS 55 Prednisone
Beaufils [7] Total 70, NS 35 26/35 NS treated 6/20 (23%) NS 55%
Non-NS 35 Prednisone Non-NS 9%
Pei [8] Total N 5 55 Prednisone 7/18 (39%) No remission 45%
NS 30 Remission 4%
Non-NS 25
Rydel [11] 81, NS 60 36/60 treated 15/30 (50%) If remission 0%
Non-NS 21 Prednisone No remission 59%
Untreated NS 30%
Miyata [12] 32 NS Prednisone 18/32 (56%) Mesangial
hypercellularity
associated with
poor prognosis
Nagai [6] Total N 5 17 8/12 NS treated 4/9 (44%) No treatment or no
NS 12 Prednisone remission 63%
Level 5
Banfi [9] 59 Prednisone 20/27 (74%)
(all NS) N 5 27
Prednisone 6 16/32 (50%)
Cytotoxic N 5 32
Korbet [4] Total 5 46, NS 29 16/29 NS treated 8/16 (50%)
Non-NS 17 Prednisone
Jenis [17] Total 5 11 Prednisone 6 2/6 (33%)
NS 9 Azathioprine
Velosa [5] 32 Prednisone 11/26 (42%)
Newman [3] Total 5 17, NS 7 Prednisone 3/6 (50%)
Lim [18] 10 Prednisone 0/10 (0%)
receiving prednisone for a median of three weeks [18]. a complete remission had preservation of renal function,
whereas the probability of CRF was 45% in those whoHowever, Korbet, Schwartz and Lewis reported a 50%
response rate (of 16 patients with nephrotic syndrome) had not responded or who were not treated. This level
4 study showed that the probability of remission with aand noted that some responses occurred by an average
of 3.75 months (range 1 to 10 months), and complete long duration of therapy was as likely in adults (39%)
as it was in children (44%) with FSGS and that age wasremission occurred at 5.75 to 6.75 months in the three
patients who had complete remission [4]. Treatment in- not a factor in treatment response or long-term outcome.
Physician bias was likely the reason for only 33% ofcluded 60 mg/day of prednisone for a minimum of one
month. In comparing patients who had a remission with adults being given a trial of therapy compared with 90%
of children.those who were not treated or had no response, there
was a significant difference in the change in renal func- The same group of investigators reported that the inci-
dence of FSGS was much lower in older patients (moretion over time that favored the treatment-response
group. than 60 years) undergoing renal biopsy (17 of 822 biop-
sies or 2%) even though the prevalence of nephroticIn several studies, response rates varied between 2 to
94%, but details on the dose of prednisone and duration syndrome in patients coming for renal biopsy was similar
to younger patients [6]. Of the 17 older patients, 9 hadof treatment were not included [3, 5, 7, 12, 16, 17].
The importance of dose and duration of therapy and received treatment. Four (44%) achieved complete re-
mission; there were no relapses in those patients whothe possibility of physician bias in the undertreatment
of adults with FSGS compared with children was put achieved remission (mean follow-up was 37 months), and
none of them progressed to renal failure. No untreatedforth by Pei et al in 1987 in a report that included 55
adult patients [8]. Treatment with prednisone (with or patients had a remission, and 9 of the 14 untreated or
nonresponders-to-treatment did progress. The treatmentwithout cytotoxic drugs) was given to 18 adult patients.
The median duration of treatment was six months. Pred- that these patients had received was prednisone, alone
or combined with cytotoxic therapy, and the maximumnisone dosages varied greatly, from 0.3 to 2 mg/kg/day.
Seven adults had complete remissions. The average fol- dose was 100 mg prednisone alternate days. The mean
time to remission was four months. This level 4 study islow-up was five years, and 96% of the patients who had
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consistent with the study results from younger patients 25]. Although CsA can be beneficial in inducing remis-
sion, relapse is common after tapering or discontinuingin the Toronto Glomerulonephritis Registry reported by
Pei et al [8]. the drug.
Ponticelli reported a prospective trial in which 44 pa-In 1995, Rydel et al reported a retrospective assess-
ment of 81 patients, including 60 with nephrotic syn- tients with nephrotic syndrome were randomized to CsA
or standard therapy [21]. Patients had been classified asdrome [11]. Thirty patients had received treatment, and
15 responded (10 had complete and 5 had partial remis- steroid resistant if they had no response after six weeks
of prednisone therapy. (This definition is not consistentsions). Treatment consisted of more than 60 mg/day for
a minimum of two months, followed by a tapering sched- with the current understanding of the time course of
response to steroid therapy in FSGS.) A biopsy diagnosisule. Remission was more common in patients who re-
ceived a dose of 60 mg/day or more of prednisone for a of FSGS was made if one glomerulus with segmental
hyalinosis was seen. The treatment group received CsAlonger period of time (2.7 vs. 1.5 months for responders
and nonresponders, respectively). Remission was not in two doses per day: 5 mg/kg/day for adults and 6 mg/
kg/day for children. Treatment was stopped at six monthsprompt, but most patients did respond by four months
of treatment. Prognostic factors associated with the de- in nonresponders. For responders, the dose was reduced
by 25% every two months so that the drug was ultimatelyvelopment of CRF were the degree of interstitial fibrosis
on renal biopsy and an elevated serum creatinine level stopped after 12 months. The control group received
only supportive therapy. Rescue treatment with cortico-at the time of biopsy. These prognostic factors did not
predict response to therapy. This level 4 study reinforced steroids was allowed for patients of both groups if there
was a rapid decline in renal function. Of the 44 nephroticthat treatment of FSGS with a high dose of prednisone
could effect a complete or partial remission in adult patients, only 19 had biopsy-proven FSGS; 10 received
CsA, and 9 were in the control group [21]. Three CsA-patients, but the treatment must be continued for four
to six months; attaining remission with treatment was treated patients attained complete remission, and four
had partial remissions. Three patients in the controlassociated with a better long-term prognosis.
A series of 14 patients with collapsing FSGS was re- group had partial remissions, but their diagnoses were
not itemized in the report. Relapses were common whenported by Detwiler et al [19]. Only four received treat-
ment with corticosteroids (one of these four also received the CsA was stopped; only two of the seven responders
in the CsA group were in remission at the end of monthcytotoxic therapy), and only one had a complete remis-
sion (level 6 evidence). A recent study of 43 patients 12 when CsA was stopped. Follow-up 12 months thereaf-
ter was incomplete, but one of the two responders had(both children and adults) with collapsing FSGS found
that none of the 26 patients treated with prednisone relapsed to nephrotic range proteinuria; data on the
other patient were not reported. Although the probabil-alone benefited. When compared with age-matched con-
trols with classic FSGS, the collapsing variant was more ity of attaining remission was greater in the CsA treat-
ment group (0.65 vs. 0.16 for the control group), thererapidly progressive, with a time course of only 13.0
months to end-stage renal failure compared with 62.5 was no difference in renal function between the groups
at one year. Specific data for the FSGS patients weremonths (level 5 evidence) [20].
In summary, prednisone treatment at approximately not presented. In this study, the subgroup of FSGS pa-
tients was small (total N 5 19); the evidence was graded1 mg/kg or 60 mg/day can induce a remission but must be
given for six months before concluding that the patient is as level 3.
In a later prospective trial, Ponticelli compared CsAsteroid resistant.
with cyclophosphamide. Seventy-three patients with
Recommendation 2 steroid-dependent, frequently relapsing nephrotic syn-
drome were randomized to CsA for nine months or cy-The use of cyclosporine A (CsA) at doses of approxi-
mately 5 mg/kg/day may be effective in reducing urinary clophosphamide for eight weeks [26]. This study included
11 adults and 55 children with either minimal changeprotein excretion. Relapse after reducing the dose or
stopping CsA is very common (grade B). Long-term use disease or FSGS. Not all patients had a renal biopsy for
diagnosis, and hence, it is not clear which results areof CsA may be required to maintain remission (grade D).
applicable to the adult FSGS patients. Therefore, the
Evidence evidence relevant to FSGS cannot be assessed and no
recommendations can be made.Prospective studies have not been conducted to com-
pare corticosteroid therapy with placebo therapy. How- Open trials of CsA have been reported, but there were
small numbers of patients with FSGS (level 4 studies)ever, the prospective studies shown in Table 3 were de-
signed to recruit patients who had failed a trial of [22–25]. Lee et al conducted a prospective study with 30
patients, but only five had FSGS [22]. Four respondedcorticosteroid therapy and to assess the addition or sub-
stitution of either a cytotoxic agent or cyclosporine [21– to CsA therapy, but two relapsed on tapering or with-
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Table 3. Cyclosporine A (CsA) studies
Level of # FSGS adults Remission on Remission on
evidence Author [Ref] treated Treatment CsA control
Level 3
Ponticelli [21] 10 treated CsA for 12 months vs. CR 3 adults CR 0
9 control supportive PR 3 adults PR3a
Level 4
Lee [22] 5 CsA for 8 months CR 4 n/a
Walker [23] 7 adults CsA 4–6 months vs. CR 0
(total 9) supportive PR 6b
Level 5
Meyrier [24] 46 children CsA 6 Pred 11 (CR 1 PR) n/a
Level 6
Green [25] 3 adults CsA CR 1, PR 1
(total 9)
Abbreviations are: CR, complete remission; PR, partial remission; Pred, prednisone; FSGS, focal segmental glomerulosclerosis.
a Diagnosis of responders not reported
b Age of responders not reported
drawal of CsA. Walker and Kincaid-Smith reported a Recommendation 3
randomized cross-over study comparing CsA treatment The use of cytotoxic therapy (cyclophosphamide and
for four to six months with standard care in nine patients chlorambucil) may be considered as second-line therapy
(7 adults) [23]. The standard care for this study included (grade D), but the evidence is not conclusive.
warfarin, which is distinct from control groups in other
studies. CsA was given in a dosage of 5 to 10 mg/kg/day. Evidence
None of the patients had a complete remission, but six The few articles regarding the use of cytotoxic agents
had a reduction in urinary protein excretion while on in adults or children with FSGS are summarized in Table
CsA. No patients responded to their standard care. This 4 [9, 27–29]. In Banfi et al’s retrospective review of FSGS
report did not clarify if the six responders were adults patients with nephrotic syndrome [9], patients were sepa-
or children. In 1990, Green et al described nine adult rated into three groups based on treatment received.
patients (three with FSGS) who received treatment with Group A was treated with prednisone alone. Group B
CsA for a maximum of 12 months in twice daily doses was treated with prednisone 1 mg/kg/day and either
(6 to 10 mg/kg/day, mean dose 6.7 mg/kg/day; level 6 chlorambucil, cyclophosphamide, or azathioprine, and
evidence) [25]. Two FSGS patients responded: one com- Group C was treated with low-dose prednisone therapy
plete and one partial remission. The third FSGS patient (0.2 to 0.3 mg/kg/day) and either azathioprine or cyclo-
was reported as not having responded after two months phosphamide. Of the 19 patients in group B, 9 had com-
of CsA therapy. plete remissions, and 2 had partial remissions. Five of
In a single report, Meyrier et al combined two open the 13 patients in group C had complete remissions. The
trials with a total of 112 adult patients with nephrotic response rates in the three groups were 74, 58, and 38%,
syndrome [24]. Patients were classified as steroid depen- respectively. The author commented that it would not
dent (6 with FSGS) or steroid resistant (40 with FSGS). be appropriate to compare the response rates statistically
In the first study, patients received CsA in two doses across the three groups, but did state that relapses oc-
daily (5 mg/kg/day). In the second study, patients re- curred more frequently in group A and remissions ap-
ceived low-dose prednisone (0.2 mg/kg/day) and CsA (5 peared more stable in the two groups that received cyto-
mg/kg/day). At six months, the FSGS patients who were toxic therapy.
steroid resistant had the lowest response rate (21%). With the dearth of studies with adult patients, three
The data on maintenance of remission after withdrawal studies involving children were reviewed. Tarshish et
of CsA were not presented according to diagnosis, and al reported a prospective level 1 study [27] comparing
it is unknown if any of the 6 patients with maintained prednisone therapy to prednisone combined with cyclo-
remission out of the 11 patients whose CsA was discon- phosphamide 2.5 mg/kg/day in 60 children. The response
tinued had FSGS. Similarly, of the 27 patients followed rate was similar in the two groups. Two level 4 studies
for a minimum of 12 months, it is not stated how many demonstrated that treatment with cyclophosphamide or
had FSGS. Although these prospective open studies in- chlorambucil was associated with remissions. Geary et
cluded 46 patients with FSGS, clear data for this specific al reported on 29 children who received cyclophospha-
mide for 90 days (at a dose of 2.5 mg/kg/day) [28]; ansubgroup were not presented. Therefore, this report is
classified as only level 5 evidence. overall 48% response rate was achieved. Tune et al also
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Table 4. Cytotoxic therapy
Level of
evidence Author [Ref] # Subjects Treatment Result Comment
Level 1
Tarshish [27] 60 children Prednisone vs. predni- No difference between Loss of renal func-
sone & cyclophospha- therapies tion in 36% and
mide 57% of patients
Level 3
Banfi [9] Total 59 adults Prednisone & cytotoxic Group B 58% Responders to ther-
Group B 519 vs. low dose predni- Group C 38% apy were less
Group C 513 sone and cytotoxic likely to lose
renal function
Level 4
Geary [28] Total529 Cyclophosphamide 48% overall 1/7 responders vs.
NS 20 2.5mg/kg/day for 7/8 non-responders
90 days developed CRF
Tune [29] 32 children i.v./oral steroid & 66% complete
cytotoxic remission
reported an excellent response to cyclophosphamide (2.0 (level 2 evidence) [35]. Recurrence was found to occur
within 24 hours of transplantation. In a report of nineto 2.5 mg/kg/day) or chlorambucil (0.15 to 0.2 mg/kg/
patients treated with plasmapheresis for post-transplantday) given for 8 to 12 weeks [29]. Of the 32 children
recurrence [36], a lasting remission could be attained bytreated, 21 (66%) had a complete remission. However,
instituting treatment immediately; otherwise, remissionscyclophosphamide therapy was tested in a randomized
were transient (level 6 evidence).clinical trial of 60 children, 30 of whom were randomized
to receive cytotoxic therapy. All of the children received
concurrent treatment with prednisone. No significant ef- SUMMARY
fect was recognized (level 1 evidence). Cameron et al
Studies on the treatment of nephrotic syndrome, eitherreported a review of 40 patients, including 28 adults, but
primary treatment or secondary treatment after a faileddetails of treatment and response were not provided [30].
trial of prednisone, have included patients with FSGS.However, a five-year survival rate of 75% was reported.
However, specific information on the FSGS patients isThe conflicting data from these studies make formulation
often not clear, and the number of FSGS patients inof a recommendation difficult.
these trials has been small. No prospective studies have
specifically assessed the use of prednisone. Reports ofRecommendation 4
case series support the use of prednisone at an initialPlasmapheresis or protein adsorption may be recom-
dose of 60 mg/day for a minimum of four months; pa-mended for renal transplant patients with recurrent
tients should not be considered prednisone resistant untilFSGS (grade D).
a six-month trial of prednisone has been completed. Pa-
tients resistant to prednisone therapy or dependent onEvidence
prednisone therapy may benefit from the use of CsA,In some patients, there may be a circulating immuno-
but the usefulness of cyclophosphamide, azathioprine,logical factor that is associated with recurrence of FSGS
or chlorambucil is not clear because there are few ran-in patients who have received a renal allograft [31, 32].
domized prospective studies on which recommendationsThe presence of the circulating factor has been identified
can be based.by using an in vitro assay and calculating permeability
of rat glomeruli. Immunoadsorption of plasma proteins Reprint requests to Ellen Burgess, M.D., Foothills Hospital, 1403-29
Street NW, Calgary, Alberta T2N 2T9, Canada.has limited temporary effectiveness in reducing urinary
protein excretion, with patients rebounding to pretreat-
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